MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Kyverna Therapeutics, Inc. (NASDAQ: KYTX)*
Organization & Developments: Kyverna Therapeutics
Parents
Kyverna Therapeutics, Inc. (NASDAQ: KYTX)*
Children
*Cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases.
*The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases
2024: Kyverna Therapeutics Aims For $200 Million IPO To Treat Autoimmune Diseases
2024: Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
2024: Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
2024: Kyverna Therapeutics Starts $100 Million IPO Effort_ seekingalpha.com
2024: Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders_seekingalpha.com
2025: Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025
Jumps
Finance & Acquisitions: Kyverna Therapeutics
Key People: Kyverna Therapeutics